Sharma P - Search Results

1

Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.

Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Tetzlaff MT, et al. Among authors: sharma p. J Cutan Pathol. 2017 Dec;44(12):1080-1086. doi: 10.1111/cup.13044. Epub 2017 Oct 13. J Cutan Pathol. 2017. PMID: 28901560

2

Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.

Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Sun J, et al. Among authors: sharma p. Cancer Immun. 2008 May 27;8:9. Cancer Immun. 2008. PMID: 18503261 Free PMC article.

3

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Carthon BC, et al. Among authors: sharma p. Clin Cancer Res. 2010 May 15;16(10):2861-71. doi: 10.1158/1078-0432.CCR-10-0569. Epub 2010 May 11. Clin Cancer Res. 2010. PMID: 20460488 Free PMC article. Clinical Trial.

4

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.

Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Fan X, et al. Among authors: sharma p. J Exp Med. 2014 Apr 7;211(4):715-25. doi: 10.1084/jem.20130590. Epub 2014 Mar 31. J Exp Med. 2014. PMID: 24687957 Free PMC article.

5

Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N. Harshman LC, et al. Among authors: sharma p. Cancer Immunol Res. 2014 Aug;2(8):714-9. doi: 10.1158/2326-6066.CIR-14-0119. Cancer Immunol Res. 2014. PMID: 25092813

6

Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Tang C, et al. Among authors: sharma p. Cancer Immunol Res. 2014 Sep;2(9):831-8. doi: 10.1158/2326-6066.CIR-14-0069. Cancer Immunol Res. 2014. PMID: 25187273 Free PMC article. Review.

7

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.

Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Gao J, et al. Among authors: sharma p. Oncogene. 2015 Oct;34(43):5411-7. doi: 10.1038/onc.2015.5. Epub 2015 Feb 9. Oncogene. 2015. PMID: 25659583 Free PMC article. Review.

8

The future of immune checkpoint therapy.

Sharma P, Allison JP. Sharma P, et al. Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172. Science. 2015. PMID: 25838373 Review.

9

From the Guest Editor: Immune Checkpoint Therapy as a Weapon Against Cancer.

Sharma P. Sharma P. Cancer J. 2016 Mar-Apr;22(2):67. doi: 10.1097/PPO.0000000000000184. Cancer J. 2016. PMID: 27111899 Free PMC article. No abstract available.

10

Immune Checkpoint Therapy and the Search for Predictive Biomarkers.

Sharma P. Sharma P. Cancer J. 2016 Mar-Apr;22(2):68-72. doi: 10.1097/PPO.0000000000000185. Cancer J. 2016. PMID: 27111900 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,775 results

Search Page

Filters